Claim That 1 in 8 US Adults Currently Use GLP-1 Drugs Like Ozempic Is an Overstatement by Half

The claim holds that approximately one in eight US adults — roughly 12 to 13% — are currently taking GLP-1 medications such as Ozempic, Wegovy, or Zepbound. That figure is off by a factor of two. The accurate number for current use is closer to one in seventeen, and the confusion traces to a single, easily misread statistic.

The primary source behind the "1 in 8" figure is the KFF Health Tracking Poll from March 2024 — and it directly contradicts the claim. KFF found that 12% of US adults reported ever having taken a GLP-1 medication, but only 6% reported currently taking one. Those are two different questions with two very different answers, and the claim uses the larger number while applying the smaller number's definition. A July 2024 follow-up by KFF confirmed the current-use figure held steady at 6%, ruling out the possibility that the March number was a one-time anomaly.

The 6% figure is not an outlier. The Gallup and West Health 2024 survey independently found approximately 6% of US adults currently using a GLP-1 drug for weight loss or diabetes management. IQVIA Institute for Human Data Science, drawing on prescription data rather than self-reported surveys, placed the total unique patient population on GLP-1 drugs in the 5 to 7% range through 2023. Trilliant Health's GLP-1 Market Report 2024 estimated roughly 9 million US patients filled at least one GLP-1 prescription in 2023 — which works out to approximately 3 to 4% of the adult population, even lower than the survey-based estimates. Across polling, insurance claims, and prescription databases, the evidence converges well below 1 in 8.

The steelman version of the claim is that GLP-1 use is surging and the "ever used" figure of 12% is genuinely striking — it shows how fast these drugs have entered American life. That part is true and worth acknowledging. The problem is precision: "ever used" includes people who tried a drug once, couldn't afford it, experienced side effects, or stopped for any other reason. It tells you about reach, not about the actual current patient population. Conflating the two inflates the current-use figure by exactly 100%.

This is a classic missing-denominator error combined with a definition swap. The claim takes a real statistic, strips away the qualifier that makes it accurate — "ever" — and presents the result as a description of present reality. Readers should watch for this pattern whenever a dramatic adoption figure appears without a clear time frame or without distinguishing between lifetime exposure and active use. With high-profile drugs generating intense media coverage, the incentive to cite the biggest available number is strong, and the distinction between "ever" and "currently" is easy to drop in a headline or social post.